Dr. Harish Kumar Verma is a seasoned Pulmonologist and Critical Care expert with over 18 years of clinical experience. He specialises in advanced respiratory care, sleep medicine, interventional pulmonology, and critical care procedures. Dr. Harish Kumar Verma is recognised for managing complex ICU cases, utilising advanced bronchoscopic techniques, and providing pulmonary rehabilitation. Dr. Harish Kumar Verma, also known for his compassionate care and evidence-based practice, has led critical care units in top hospitals and actively contributes to research in pulmonology and rheumatology.
Dr. Harish Kumar Verma
Associate Director
Respiratory & Sleep Medicine
Qualification:
MBBS, MD, DM
Experience:18+ Years
Rating:5out of 5 Patient Satisfaction Ratings
Languages:English, Hindi
About
Experience
- Senior Consultant & Incharge, Yathartha Super-speciality Hospital
- Director, Advanta Super-speciality Hospital, Rohtak
- Consultant & Head, Noble Heart & Super-speciality Hospital, Rohtak
- Consultant & Head, Teerathankar Mahaveer Medical College & Hospital, Moradabad
- Associate Consultant, Max Hospital, Saket, Delhi
Awards & Achievements
- Paper presented at APICON 2010: “Comparison of Indian C-DAS with DAS-28 in Rheumatoid Arthritis”
- Active participant in research on RA, critical care, and pulmonary interventions
- Leadership roles across multiple super-speciality hospitals in Pulmonology & ICU care
Specialization & Expertise
- Chest & Lung Disease
- Pleural Effusion
- Respiratory Diseases
- Lung Cancer & Fibrosis
- Pneumonia & TB
- Sleep Disorders
- Asthma & Allergy Disorders
- Bronchoscopy, EBUS, Thoracoscopy
- Pulmonary Rehabilitation
- Interstitial Lung Disease (ILD)
- COPD & Smoking Lung Disorders
Qualifications
- MBBS
- MD (Internal Medicine)
- DM (Pulmonary & Critical Care Medicine) from VMMC & Safdarjung Hospital, Delhi
Clinical Interests
N/A
Research
- Correlation of Intima-Media Thickness with Rheumatoid Arthritis activity – JIACM, 2011
- Hand function assessment in RA and its correlation to disease activity – Rheumatol Int, 2011
- Clinical Disease Activity Index for RA assessment – Arthritis, 2011
- Biological therapy as first-line treatment in RA – Medicine Update, 2011
- International publications of interest from India – Indian J Rheumatol, 2011
- Chemotherapy safety and drug toxicity review – EJBP Sciences, 2017
Memberships
N/A